

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/020613 A1

(51) International Patent Classification⁷: C12N 5/02

(74) Agents: HUGHES, John, E., L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, Victoria 3000 (AU).

(21) International Application Number:
PCT/AU2003/001113

(22) International Filing Date: 29 August 2003 (29.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002951082 30 August 2002 (30.08.2002) AU

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RICE, Alison, Mary [AU/AU]; 174 Gladstone Road, Highgate Hill, Queensland 4101 (AU). HART, Derek [NZ/AU]; 3 Borva Street, Dutton Park, Queensland 4102 (AU). VUKOVIC, Slavica [NZ/AU]; 43 Gainsborough Avenue, Mackenzie, Queensland 4156 (AU).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENERATION OF DENDRITIC CELLS FROM CD34⁺ PRECURSORS

(57) Abstract: The present invention relates to a method for inducing development of dendritic cells from CD34⁺ precursor cells. More particularly, the present invention relates to a method of differentiating CD34⁺ precursor cells into myeloid- and or lymphoid-dendritic cells. The present invention provides a protocol for the development of dendritic cells from a biological sample *inter alia* cord blood, bone marrow or peripheral blood CD34⁺ stem cells. The dendritic cells of the present invention are useful as therapeutic cellular agents such as in the development of vaccines and in modulating immunological responsiveness. More particularly, the present invention provides compositions which can be used for inducing a protective immune response in a subject against *inter alia* pathogenic infections, autoimmune diseases and cancer.



WO 2004/020613 A1

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

PCT/AU2003/00111303

WIPO

PCT

Applicant's or agent's file reference 12323910/EJH/LM	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/AU03/01113	International filing date (day/month/year) 29 August 2003	(Earliest) Priority Date (day/month/year) 30 August 2002
Applicant THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLAND et al		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (See Box II).

4. With regard to the **title**, ☐ the text is approved as submitted by the applicant.
☒ the text has been established by this Authority to read as follows:

GENERATION OF DENDRITIC CELLS FROM CD34+ PRECURSORS

5. With regard to the **abstract**, ☒ the text is approved as submitted by the applicant
☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ None of the figures

☐ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

- 1 -

GENERATION OF DENDRITIC CELLS FROM CD34+ PRECURSORS**BACKGROUND OF THE INVENTION****5 FIELD OF THE INVENTION**

The present invention relates to a method for inducing development of dendritic cells from CD34⁺ precursor cells. More particularly, the present invention relates to a method of differentiating and expanding CD34⁺ precursor cells into myeloid- and or lymphoid-
10 dendritic cells. The present invention provides a protocol for the development of dendritic cells from a biological sample *inter alia* cord blood, bone marrow or peripheral blood CD34⁺ stem cells. The dendritic cells of the present invention are useful as therapeutic cellular agents such as in the development of vaccines and in modulating immunological responsiveness. More particularly, the present invention provides methods for inducing a
15 protective immune response in a subject against *inter alia* pathogenic infections, autoimmune diseases and cancer using compositions comprising antigen-presenting dendritic cells.

DESCRIPTION OF THE PRIOR ART

20

Bibliographic details of references provided in the subject specification are listed at the end of the specification.

Reference to any prior art in this specification is not, and should not be taken as, an
25 acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

Dendritic cells (DC) are potent cellular activators of primary immune responses (Hart, *Blood* 90: 3245-3287, 1997). Immature myeloid DC in non-lymphoid organs react to
30 endocytose and process antigens and migrate *via* blood and lymph to T cell areas of lymphoid organs. Here, the mature cells present foreign peptide complexed to MHC Class

- 2 -

I and II to T cells and deliver unique signals for T-cell activation (immuno-stimulation). They also stimulate B lymphocytes and NK cells. DC undergo differentiation /activation during this process, lose their antigen-capturing capacity and become mature, immuno-stimulatory DC that trigger naïve T-cells recirculating through the lymphoid organs. The
5 lymphoid DC subset may have a different migration pathway and although capable of stimulating allogeneic and autologous T-lymphocytes they have been suggested to have a regulatory function (Grouard *et al.*, *J. Exp. Med.* 185: 1101-1111, 1997). As part of the differentiation/activation process, DCs up-regulate certain relatively selectively-expressed cell surface molecules such as the CMRF-44 and CD83 antigens. DC in the thymus and
10 blood that do not have an activated co-stimulating phenotype probably contribute to central and peripheral tolerance.

Blood dendritic cells (BDC) are released from bone marrow into the peripheral blood before homing to the tissues as surveillance DC for the immune system. The two major
15 subsets of BDC are myeloid DC (CD11c⁺ CD123^{-dim}) and lymphoid (CD123^{hi} CD11c⁻).

There is a need to develop a protocol for generating BDC and in particular myeloid BDC and lymphoid BDC sub-populations. Such cells are useful as potential cellular agents for use, for example, in the manufacture of vaccines or in modulating immunological
20 responsiveness. However, DC circulate in low number in the peripheral blood system and are, hence, difficult to isolate. A protocol is required, therefore, to generate a ready source of BDC.

- 3 -

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

The present invention provides a method for inducing or otherwise facilitating development of blood dendritic cells (BDC) from CD34⁺ precursor cells. Generally, the
10 CD34⁺ precursor cells are from sources such as cord blood, bone marrow or peripheral blood. Cord blood is particularly preferred. The protocol generally involves sorting CD34⁺ precursor cells into a myeloid population and/or a lymphoid population. The myeloid population is generally CD33⁺CD7⁻CD10⁻ and the lymphoid population is generally CD33⁺CD7⁺CD10⁺. One or both sub-populations of CD34⁺ precursor cells are then
15 cultured into the presence of one or more cytokines and preferably a cocktail of cytokines for a time and under conditions sufficient for CD34⁺-derived DC to develop. The myeloid DC precursors differentiate *via* either CD14 or CD1a pathways. Within the expanded population, monocytes (CD14⁺), granulocytes (CD15⁺), myeloid BDC-like cells (CD11c⁺CD123⁻) and lymphoid BDC-like cells (CD11c⁻CD123^{hi}) may develop. The latter
20 myeloid and lymphoid BDC are proposed to be potential therapeutic cellular agents for the development of vaccines and to modulate immunological responsiveness.

The present invention provides, therefore, a method for generating myeloid- or lymphoid-like BDC, said method comprising isolating CD34⁺ precursor cells, sorting into a myeloid
25 and/or lymphoid population and culturing either or both populations in the presence of one or more cytokines or functional, recombinant or chemical homologs or equivalents thereof for a time and under conditions sufficient for CD34⁺ cell expansion to occur and then isolating the CD34⁺-derived myeloid- or lymphoid-like BDC.

30 The useful cytokines are, for example, flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF and/or TNF α .

- 4 -

The ability to enrich for, or generate, myeloid- or lymphoid-like BDC permits a marked improvement over monocyte-derived DC. The isolated cells may be used to generate vaccines to induce an immunological response against specific antigens or may be used to
5 induce immunological tolerance or non-responsiveness.

The present invention provides, therefore, an isolated population of lymphoid- or myeloid-like BDC which present a peptide on their cell surface in the context of an MHC molecule. These antigen-presenting dendritic cells can then be used in vaccine development or as
10 potential therapeutic cellular agents to, for example, induce immunological tolerance or non-responsiveness or induce protective immune responses against cancers or pathogenic agents.

The present invention further contemplates the use of myeloid- or lymphoid-like BDC
15 derived from CD34⁺ precursor cells in the manufacture of a population of potential therapeutic cellular agents.

The present invention also provides vaccines comprising the isolated myeloid- or lymphoid-like BDC loaded with particular antigens.

20

Reference to a "CD" includes a "CD^{lo}" or "CD⁻" marker.

- 5 -

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graphical representation showing the growth of cord blood (CB) CD34⁺ myeloid precursors in the presence of flt3, SCF, IL-3 and IL-6 to generate an expanded
5 culture.

Figure 2 is a graphical representation showing the emergence of CD14⁺ progeny.

Figure 3 is a graphical representation showing the emergence of CD15⁺ progeny.
10

Figure 4 is a graphical representation showing the emergence of CD14⁻ CD15⁻ progeny.

Figures 5(A)-(E) are graphical representations of CD11c⁺ DC's existing in a CD14⁻-CD15⁻ population after precursor cell expansion.
15

Figure 6 is a graphical representation showing that CD11c⁺HLA-DR⁺CD123⁻CD1a⁻ cells can induce a potential mixed lymphocyte reaction (MLR).

- 6 -

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides a protocol for developing myeloid- or lymphoid-like BDC form CD34⁺ precursor cells. Reference herein to “myeloid-like BDC” and “lymphoid-like BDC” includes myeloid BDC and lymphoid BDC, respectively.

Myeloid-like BDC have the potential for inducing more potent allogenic T-lymphocyte responses compared to granulocytes or monocytes and, hence, are proposed to be useful therapeutic cellular agents in the development of vaccines and to modulate immunological responsiveness.

Accordingly, one aspect of the present invention contemplates a method for generating and expanding a population of dendritic cells, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population into CD34⁺ precursor cells, culturing the population with one or more cytokines for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating said dendritic cells from the expanded population.

In a related embodiment, the CD34⁺ precursor cell is cultured with one or more cytokines for a time and under conditions sufficient to induce differentiation and/or expansion into a specific lineage of dendritic cells. The specific lineages of dendritic cells contemplated by the methods of the present invention include, without being limited to, Langerhans cells, interstitial dendritic cells, afferent lymph veiled cells, blood dendritic cells and interdigitating cells.

In a preferred aspect, the present invention contemplates a method for generating a population myeloid- or lymphoid-like BDC, wherein the method comprises obtaining a population of CD34⁺ precursor cells, sorting this population into myeloid and/or lymphoid precursors, culturing either or both with one or more cytokines for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded culture.

- 7 -

Reference to a "biological sample" should be understood to reference any sample which contains CD34⁺ precursor cells. In this regard, the biological sample may be derivable from both human and non-human organisms. Non-human organisms contemplated by the present invention include primates, livestock animals (e.g. sheep, pigs, cows, horses, donkeys), laboratory test animals (e.g. mice, hamsters, rabbits, rats, guinea pigs), domestic companion animals (e.g. dogs, cats), birds (e.g. chicken, geese, ducks and other poultry birds, game birds, emus, ostriches), captive wild or tamed animals (e.g. foxes, kangaroos, dingoes), reptiles and fish.

10

It should be understood that the biological sample may be any sample derived from the organism which contains CD34⁺ precursor cells. This includes reference to both samples which are naturally present in the organism, such as tissue and body fluids in a mammal (for example biopsy specimens such as lymphoid specimens, blood, lymph fluid or bronchial secretions) and samples which are introduced into the body of the organism and subsequently removed, such as, for example, the saline solution extracted from the lung fluid following a lung lavage.

15

CD34⁺ precursor cells may be isolated directly from the biological sample or the sample may require some processing before the cells can be isolated. For example, a biopsy sample may require homogenisation prior to testing. CD34⁺ precursor cells may be isolated directly from blood using, for example using immunomagnetic beads coated with anti-CD34 antibodies, or the blood samples may be processed first to isolate the cellular compartment of the blood, e.g. the PBMC, prior to the CD34⁺ faction being further purified from the PBMC.

20

25

The CD34⁺ precursor cells are preferably CD34⁺ precursor cells from any convenient source. The most convenient source is cord blood. Other sources include bone marrow and peripheral blood. Yet other sources of CD34⁺ precursor cells include, stem cells, monocytes, amniotic fluid, chrionic villus and tissues.

30

- 8 -

In relation to these preferred sources of CD34⁺ precursor cells, another aspect of the present invention provides a method for generating a population of myeloid- or lymphoid-like BDC, said method comprising obtaining a population or source of CD34⁺ stem cells from cord blood, bone marrow and/or peripheral blood sorting this population into myeloid
5 and/or lymphoid precursors, culturing either or both populations with one or more cytokines for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded cell culture.

10 By "obtaining" CD34⁺ precursor cells including stem cells means enriching, selecting and/or isolating CD34⁺ cells from mixed populations of cells. The CD34⁺ precursor cell culture does not have to be pure or solely or substantially CD34⁺ cells but a substantially homologous population of CD34⁺ cells is certainly preferred. The present invention extends, however, to heterogenous mixtures of cells provided the mixture comprises
15 CD34⁺ precursor-cells and in particular CD34⁺ stem cells. Sorting of the CD34⁺ precursor cells provides a population of myeloid precursors having characteristic markers CD33⁺CD7⁻CD10⁻ and a population of CD33⁺CD7⁺CD10⁺ lymphoid precursors. Either or both populations may then be subject to expansion-enhancing conditions. Although either myeloid or lymphoid precursor CD34⁺ cells may be employed in the practice of the present
20 invention, up to the present time, myeloid precursor cells are particularly preferred. Myeloid precursor CD34⁺ cells give rise to myeloid-like BDC which are CD11c⁺CD123⁻ cells. Lymphoid precursor CD34⁺ cells have the potential to give rise to lymphoid-like BDC which are CD11c⁻CD123^{hi}. Conveniently, CD34⁺ cells may be collected by any convenient means such as being immobilized to magnetic particles or FACS sorting
25 microspheres.

The cells may be isolated directly from a biological sample, for example using immunomagnetic beads. Alternatively, the sample may be manipulated first to facilitate the isolation of the CD34⁺ precursor cells.

30

Sorting is preferably conducted with a flow cytometer which comprises a "fluorescence-

- 9 -

activated cell sorter" (FACS) [see, for example, "*Methods in Cell Biology*" Vol. 33, Darzynkiewica, Z. and Crissman, H.A., eds., Academic Press) and Dangi and Herzenberg, *J. Immunol. Methods* 52: 1-14, 1982].

- 5 Accordingly, in a preferred embodiment, the present invention contemplates a method for generating a population of myeloid-like BDC, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population to obtain myeloid precursor cells characterized by being CD33⁺CD7⁺CD10⁻, culturing this population with one or more cytokines for a time and under conditions sufficient to obtain a CD34⁺-derived
10 cell expansion culture and then isolating myeloid-like BDC characterized by being CD11c⁺CD123⁻ from the expanded cell culture.

Preferably, the CD34⁺ precursor cells are derived or obtained from cord blood. However, precursor cells from bone marrow and/or peripheral blood are also contemplated by the
15 present invention.

The CD34⁺ cell expansion conditions include incubating or culturing the cells in the presence of one or more cytokines. Preferably, a cocktail of two or more cytokines is employed. Cytokine employed by the methods of the present invention, include, without
20 being limited to, flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF, TNF- α , IL-4, TNF- β , LT- β , IL-2, IL-7, IL-9, IL-15, IL-13, IL-5, IL-1 α , IL-1 β , IFN- γ , IL-10, IL-17, IL-16, IL-18, HGF, IL-11, MSP, FasL, TRAIL, TRANCE, LIGHT, TWEAK, CD27L, CD30L, CD40L, APRIL, TALL-1, 4-1BBL, OX40L, GITRL, IGF-I, IGF-II, HGF, MSP, FGF-a, FGF-b, FGF-3-19, NGF, BDNF, NTs, Tpo, Epo, Ang1-4, PDGF-AA, PDGF-BB, VEGF-A, VEGF-B, VEGF-
25 C, VEGF-D, PIGF, EGF, TGF- α , AR, BTC, HRGs, HB-EGF, SMDF, OB, CT-1, CNTF, OSM, SCF, Flt-3L, M-CSF, MK and PTN or their functional, recombinant or chemical equivalents or homologues thereof. Although a range of cytokines may be employed, particularly useful cytokines are those selected from flt3, SCF, IL-3 and IL-6 or their functional, recombinant or chemical equivalents or homologs. Other useful cytokines
30 include GM-CSF, G-CSF and TNF α .

- 10 -

Accordingly, another aspect of the present invention contemplates a method for generating a population of myeloid- or lymphoid-like BDC, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population into myeloid and/or lymphoid precursors, culturing either or both populations with one or more cytokines
5 selected from flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF and TNF α or their functional, recombinant or chemical equivalents or homologs for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded cell culture.

10 Preferably, the CD34⁺ precursor cells are CD34⁺ cord blood-derived stem cells. Even more preferably, the cells generated are myeloid-like BDC characterized by being CD11c⁺CD123⁻.

A range of cytokines or functional equivalents may be employed and the present invention
15 extends to any and all conditions which facilitate cell expansion. In a most preferred embodiment, however, a cocktail of cytokines comprising flt3, SCF, IL-3 and IL-6 is employed.

Accordingly, another aspect of the present invention contemplates a method for generating
20 a population of myeloid- or lymphoid-like BDC, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population into myeloid and/or lymphoid precursors, culturing either or both populations with a mixture of cytokines comprising flt3, SCF, IL-3 and IL-6 or their functional, recombinant or chemical
25 equivalents or homologs of any or all of the above for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded cell culture..

In another preferred embodiment, the present invention provides a method for generating a population of myeloid- or lymphoid-like BDC, said method comprising obtaining a
30 population or source of CD34⁺ stem cells from cord blood, bone marrow and/or peripheral blood, sorting this population into myeloid and/or lymphoid precursors, culturing either or

- 11 -

both populations with a mixture of cytokines comprising flt3, SCF, IL-3 and IL-6 and optionally one or more of GM-CSF, G-CSF and TNF α or their functional, recombinant or chemical equivalents or homologs of any or all of the above for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating
5 myeloid-like BDC or lymphoid-like BDC from the expanded cell culture.

In yet another embodiment, the present invention contemplates a method for generating a population of myeloid-like BDC, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population to obtain myeloid precursor cells
10 characterized by being CD33⁺CD7⁻CD10⁻, culturing both populations with a mixture of cytokines comprising flt3, SCF, IL-3 and IL-6 and optionally one or more of GM-CSF, G-CSF and TNF α or their functional, recombinant or chemical equivalents or homologs of any or all of the above for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC characterized by being
15 CD11c⁺CD123⁻ from the expanded cell culture.

The myeloid- and lymphoid-like BDC populations obtainable by the method of the present invention are proposed to be useful in the generation of vaccines and to modulate immunological responsiveness.

20

The present invention provides, therefore, a population of cells comprising myeloid- or lymphoid-like BDC, said population of cells isolated or enriched from an expanded culture of CD34⁺ cells generated from myeloid or lymphoid precursor cells sorted from a population of CD34⁺ precursor cells and cultured in the presence of one or more cytokines.

25

Reference to a "population" includes reference to an isolated culture comprising a homogenous, a substantially homogenous or a heterogenous culture of cells. Preferably, the population of myeloid-or lymphoid-like cells is substantially homogenous for one or either of these types of cells. Generally, a "population" may also be regarded as an
30 "isolated" culture of cells.

- 12 -

In a preferred embodiment, a cocktail of cytokines is used comprising two or more of flt3, SCF, IL-3 and/or IL-6 or functional, recombinant or chemical equivalents thereof. Even more preferably, a cocktail comprises at least all of the flt3 ligand, SCF, IL-3 and IL-6.

- 5 In a particularly preferred embodiment, the present invention further extends to a population of myeloid-like BDCs, said population generated by the method of obtaining a population or source of CD34⁺ precursor cells, sorting this population into myeloid and/or lymphoid precursors, culturing either or both populations with one or more cytokines selected from flt3, SCF, IL-3 and IL-6 and optionally one or more of GM-CSF, G-CSF n
- 10 TNF α or their functional, recombinant or chemical equivalents or homologs for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded cell culture.

- The isolated, population of myeloid- and/or lymphoid-like cells are useful in the
- 15 manufacture of vaccines. In one embodiment, the cells are exposed, incubated or cultured with one or more antigens for a time and under conditions for the antigen to be taken up by the cells and presented in the context of peptide associated with an MHC molecule expressed on the cells surface. In one aspect of the present invention, the peptide is presented in the context of an MHC class I molecule present on the surface of the dendritic
- 20 cell, wherein the antigen-presenting dendritic cell specifically targets CD8⁺ cytotoxic T lymphocytes for stimulation and subsequent expansion of a CD8⁺-specific T cell immune response. Alternatively, the peptide is presented in the context of an MHC class II molecule on the dendritic cell surface, wherein the antigen-presenting dendritic cell specifically targets CD4⁺ T helper cells resulting in the stimulation and expansion of a
- 25 CD4-specific T cell immune response. In a most preferred embodiment, the dendritic cell presents peptides from a specific protein or organism in the context of both MHC class I and MHC class II molecules. Co-expression in this context provides for the generation of both a CD4⁺ and CD8⁺ T cell response specific for the antigen of interest. Such a dual response is preferred in the establishment of a protective immune response.

30

Peptides presented in conjunction with the MHC molecules may be loaded either by

- 13 -

- incubating the dendritic cells with peptide fragments derived from the antigen of interest which are able to bind directly to the MHC molecule, e.g. such as a synthetically produced peptide comprising a minimal epitope. Methods for the generation of such peptides will be appreciated by one of skill in the art. Alternatively, polypeptides, entire proteins, cells, or
- 5 fragments thereof may be mixed with the dendritic cells or precursors to the dendritic cells. These molecules can then be internalised by the dendritic cells, wherein the proteins/polypeptides are internally processed and eventually presented on the dendritic cell surface in the context of either a class I or class II MHC molecule.
- 10 Alternatively, the antigen-presenting dendritic cell may be transfected with a polynucleotide encoding a polypeptide (or portion or other variant thereof) such that the polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein.
- 15 Alternatively, a gene delivery vehicle that targets the antigen-presenting dendritic cell may be administered to a subject, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., 1997, *Immunology and Cell Biology* 75:456-460.
- 20 Antigen loading of dendritic cells may be achieved by incubating dendritic cells or the CD34⁺ precursor cells with a polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that aids in the expression of (e.g., a
- 25 carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Upon re-introduction of the antigen-load myeloid- or lymphoid-like BDC, an immune response is generated against the antigens. These antigens may be derived from

30 pathogenic, microorganisms, parasites, cancer cells or other sources.

- 14 -

Using the methods of the present invention, protective immune responses can be generated against foreign proteins and polypeptides, in addition to inducing tolerance to self-proteins. As used herein, "protective immunity" should be understood to reference the development of an immune response against a target antigen. Such responses can be measured using immunological assays, such as proliferation assays, cytotoxic T cell assays, including chromium release assays, assays which measure the production of cytokines, such as IFN- γ , TNF- α , and IL-2. The methods for performing such assays are well known to those experienced in the field of immunology and are described in *Immunology* (Roit, Brostoff, Male: 6th Edition).

10

In one aspect, protective immunity is induced against a specific pathogen. Such pathogens include, without being limited to viruses, bacteria, fungi, ectoparasites, mycoplasmas, *Archea*, algae, oomycetes, slime molds, nematodes and amoebae.

15 In a preferred aspect, the antigen-presenting dendritic cells generated using the methods of the present invention are specific for a virus selected from the group consisting of Human Immunodeficiency Virus (HIV), the human papilloma virus, Epstein-Barr virus, the polio virus, the rabies virus, the Ebola virus, the influenza virus, the encephalitis virus, smallpox virus, the rabies virus, the herpes viruses, the sendai virus, the respiratory syncytial virus, the
20 othromyxoviruses, the measles viruses, the vesicular stomatitis virus, visna virus and cytomegalovirus.

In a related aspect, the antigen-presenting dendritic cells generated using the methods of the present invention are specific for a fungi selected from the group consisting of
25 *Acremonium* spp., *Aspergillus* spp., *Basidiobolus* spp., *Bipolaris* spp., *Blastomyces dermatidis*, *Candida* spp., *Cladophialophora carrionii*, *Coccidioides immitis*, *Conidiobolus* spp., *Cryptococcus* spp., *Curvularia* spp., *Epidermophyton* spp., *Exophiala jeanselmei*, *Exserohilum* spp., *Fonsecaea compacta*, *Fonsecaea pedrosoi*, *Fusarium oxysporum*, *Fusarium solani*, *Geotrichum candidum*, *Histoplasma capsulatum* var.
30 *capsulatum*, *Histoplasma capsulatum* var. *duboisii*, *Hortaea werneckii*, *Lacazia loboi*, *Lasiodiplodia theobromae*, *Leptosphaeria senegalensis*, *Madurella grisea*, *Madurella*

- 15 -

mycetomatis, *Malassezia furfur*, *Microsporum* spp., *Neotestudina rosatii*, *Onychocola canadensis*, *Paracoccidioides brasiliensis*, *Phialophora verrucosa*, *Piedraia hortae*, *Piedra iahortae*, *Pityriasis versicolor*, *Pseudallesheria boydii*, *Pyrenochaeta romeroi*, *Rhizopus arrhizus*, *Scopulariopsis brevicaulis*, *Scytalidium dimidiatum*, *Sporothrix schenckii*, *Trichophyton* spp., *Trichosporon* spp., Zygomycete fungi, *Absidia corymbifera*, *Rhizomucor pusillus* and *Rhizopus arrhizus*.

In yet another aspect, the antigen-presenting dendritic cells generated using the methods of the present invention are specific for a bacterial protein, wherein the bacterial protein is derived from a bacterium selected from the group consisting of *Bacillus anthracis*, *Bordetella pertussis*, *Vibrio cholerae*, *Escherichia coli*, *Shigella dysenteriae*, *Clostridium perfringens*, *Clostridium botulinum*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Pseudomonas aeruginosa*, *Bacillus anthracis*, *Bordetella pertussis*, *Staphylococcus aureus* and *Streptococcus pyogenes*.

In yet another aspect, the antigen presenting dendritic cells of the present invention are specific in inducing immunity against a variety of cancers in a subject. The methods of the present invention contemplate providing protection against cancers selected from the group consisting of, without being limited to, ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumours, Breast Cancer, CNS tumours, Carcinoid Tumours, Cervical Cancer, Childhood Brain Tumours, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma-protuberans, Desmoplastic-Small-Round-Cell-Tumour, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer,

- 16 -

Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumour, Genitourinary Cancers, Germ Cell Tumours, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer,

5 Hereditary Breast Cancer, Histiocytosis, Hodgkin's Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's-Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Hodgkin's Lymphoma, Non-

10 Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumour-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage

15 Syndrome, Non-Melanoma Skin Cancer, Non-Small-Cell-Lung-Cancer-(NSCLC), Ocular Cancers, Oesophageal Cancer, Oral cavity Cancer, Oropharynx Cancer, Osteosarcoma, Ostomy Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral-Neuroectodermal-Tumours, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare-cancers-and-associated-disorders, Renal Cell

20 Carcinoma, Retinoblastoma, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumours, Squamous-Cell-Carcinoma-(skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-

25 Cancer-(renal-pelvis/-ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's-Macroglobulinemia, Wilms' Tumour.

The present invention also contemplates methods for protecting a subject against

30 autoimmune diseases. As used herein, reference to an autoimmune disease, includes inducing protection against any disease caused the immune system mistakenly attacking

- 17 -

self molecules, targeting the cells, tissues, and organs of a person's own body. Protection against autoimmune diseases contemplated by the present invention include, without being limited to, those selected from the group consisting of Addisons Disease, Allergies, Anemia, Ankylosing Spondylitis, Arthritis, Celiac Disease, Crohns Disease, Diabetes, Endometriosis, Fibromyalgia, Graves Disease, Hashimotos Disease, Hypothyroidism, Immune Diseases, Lupus, Lymphoma, Meniere's Disease, Multiple Sclerosis, Oral Diseases, Osteoporosis, Pleurisy, Psoriasis, Reiters Syndrome, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogrens Syndrome, Thrush, Vitiligo, Alopecia Areata, Antiphospholipid Syndrome (APS), Behcet's Disease, Ulcerative Colitis, Goodpasture Syndrome, Graft Versus Host Disease, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myositis, Pemphigus Vulgaris, Primary Biliary Cirrhosis, Rheumatic Fever, Vasculitis and Wegener's Granulomatosis.

Vaccines are also useful in the treatment or prophylaxis of inflammatory bowel disease and to increase levels of immune responsiveness such as during stress (e.g. surgery) or chemotherapy.

Alternatively, the myeloid- or lymphoid-like BDC may be loaded with sub-optimal levels of antigen or loaded with a super dose which can result in the induction of immuno-tolerance or immuno-non-responsiveness.

Accordingly, another aspect of the present invention contemplates a method of vaccinating a subject against an antigen including a cell carrying the antigen, said method comprising loading a myeloid- or lymphoid-like BDC with an amount of said antigen which will induce an immune response wherein said myeloid- or lymphoid-like BDC or its parent is prepared by the method of generating a population of lymphoid- or myeloid-like BDC, said method comprising obtaining a population or source of CD34⁺ precursor cells, sorting this population into myeloid and/or lymphoid precursors, culturing either or both populations with one or more cytokines for a time and under conditions sufficient to obtain a CD34⁺-derived cell expansion culture and then isolating myeloid-like BDC or lymphoid-like BDC from the expanded cell culture.

- 18 -

Preferably, the CD34⁺ precursor cells are CD34⁺ stem cells from cord blood.

Preferably, the myeloid and/or lymphoid precursor cells are cultured in the presence of a
5 cytokine selected from the list comprising flt3, SCF, IL-3 and IL-6. Even more preferably,
the cells are cultured in a cocktail of cytokines comprising flt3-ligand, SCF, IL-3 and IL-6.
Other cytokines in the cocktail may optionally include GM-CSF, G-CSF and TNF α .

In a most preferred embodiment, the present invention contemplates a method of
10 vaccinating a subject against an antigen including a cell carrying the antigen, said method
comprising loading a myeloid-like BDC with an amount of said antigen which will induce
an immune response wherein said myeloid-like BDC or its parent is prepared by the
method of generating a population of myeloid-like BDC by obtaining a population or
source of CD34⁺ precursor cells, sorting this population into myeloid precursors, culturing
15 this population with one or more cytokines for a time and under conditions sufficient to
obtain a CD34⁺-derived cell expansion culture, loading the myeloid-like BDC with an
antigen and then introducing the BDC to the subject. Generally, the subject is the source of
the CD34⁺ precursor cells.

20 In another embodiment, as indicated above, the myeloid- or lymphoid-like BDC are loaded
with sub-optimal or excess doses of antigen to induce immuno-tolerance or non-
responsiveness.

The present invention provides, therefore, compositions for modulating the immune
25 system or a response thereby, said composition comprising a myeloid- or lymphoid-like
BDC generated by the method as hereinbefore described or are progeny cells of these
generated cells. Such cells may be optionally loaded with antigen to induce a protective
immune response or with sub- or over-optimum levels to induce immuno-tolerance or non-
responsiveness.

30 Generally, although not exclusively, when used in therapy, autologous BDC are used

- 19 -

relative to the subject.

The preferred subject is a human but the present invention extends to other primates, livestock animals (e.g. sheep, cows, horses, pigs, donkeys, goats), companion animals (e.g. dogs, cats) or laboratory test animals (e.g. mice, rabbits, guinea pigs, hamsters) and avian species (e.g. chickens, game birds or aviary birds).

The present invention further contemplates the use of myeloid- or lymphoid-like BDC generated as hereinbefore described in the manufacture of a vaccine or therapeutic cellular agent.

In addition to the antigen-presenting dendritic cells generated using the methods of the present invention, compositions used in the treatment of a subject may additionally comprise adjuvants. As used herein, "adjuvant" includes those adjuvants commonly used in the art to facilitate the stimulation of an immune response. Examples of adjuvants include, but are not limited to, helper peptide; aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (Smith-Kline Beecham); QS-21 (Aquila); MPL or 3d-MPL (Corixa Corporation, Hamilton, Mont.); LEIF; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A; muramyl tripeptide phosphatidyl ethanolamine or an immunostimulating complex, including cytokines (e.g., GM-CSF or interleukin-2, -7 or -12) and immunostimulatory DNA sequences. In some embodiments, such as with the use of a polynucleotide vaccine, an adjuvant such as a helper peptide or cytokine can be provided via a polynucleotide encoding the adjuvant.

Such a vaccine or therapeutic cellular agent is also regarded herein as a medicament.

In one embodiment, the vaccine or therapeutic cellular agent is useful for the treatment or

- 20 -

prophylaxis of cancer infection by pathogenic microorganism, parasite or virus or to induce immuno-tolerance or non-responsiveness such as in the treatment or prophylaxis of autoimmune disease conditions.

- 5 The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time, or to inhibit infection or disease due to infection. Thus, the composition is administered to a patient in an amount sufficient to elicit an effective immune response to the specific antigens and/or to alleviate, reduce, cure or at least partially arrest symptoms and/or complications from
10 the disease or infection. An amount adequate to accomplish this is defined as a "therapeutically effective amount."

The dose will be determined by the activity of the composition produced and the condition of the patient, as well as the body weight or surface areas of the patient to be treated. The
15 size of the dose also will be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a particular composition in a particular patient. In determining the effective amount of the composition to be administered in the treatment or prophylaxis of diseases such as those contemplated by the present invention, the physician needs to evaluate the production of an immune response against the virus,
20 progression of the disease, and any treatment-related toxicity.

The present invention is further described by the following non-limiting Examples.

- 21 -

EXAMPLE 1***Generation of myeloid-like BDC***

Sorted myeloid ($CD33^+CD7^-CD10^-$) and lymphoid ($CD34^+CD33^{+/-}CD7^+CD10^+$) precursors from enriched cord blood $CD34^+$ cells were cultured in 24-well plates ($4-5 \times 10^4$ cells/ml) in H2000 serum free medium supplemented with a cocktail of cytokines (flt3-ligand 50 ng/ml, SCF 50 ng/ml, IL-3 10 ng/ml and IL-6 10 ng/ml) for 2-3 weeks. Figure 1 shows the growth of cord blood $CD34^+$ precursors in the presence of the cytokines. The progeny were assessed for phenotype on days 6-8 and every second day thereafter and also for their capacity to induce allogeneic T lymphocyte responses on days 8-12, of culture.

The presence of $CD11c^+$ myeloid-like BDC in a $CD14^-CD15^-$ population is shown in Figures 5A-E.

Figures 2-4 show the emergence of $CD14^+$, $CD15^+$ and $CD14^-CD15^-$ populations and Figure 5 shows the emergency of $CD11c^+CD14^-CD15^-$ progeny.

Figure 6 shows $CD11c^+HLA-DR^+CD123^-CD1a^-$ cells can induce a mixed lymphocyte reaction (MLR).

Peak $CD34^+$ derived cell expansion was observed on day 10-13 of culture, resulting in a 70 to 100 fold increase in cell number. Thereafter, cell number decreased steadily, although viable cells (>60%) could be observed for up to 3 weeks. There was no evidence of lineage differentiation during the initial period (4-6 days) of cell expansion. Monocytes ($CD14^+$ cells), granulocytes ($CD15^+$ cells), and myeloid-like BDC ($CD11c^+CD123^-$ cells) appeared subsequently (days 6-8) and were maintained during the period of culture. Only the $CD11c^+CD123^-$ progeny were capable of inducing potent allogeneic T lymphocyte responses, compare to monocytes and granulocytes.

- 22 -

EXAMPLE 2***Yield of CD34⁺, myeloid/lymphoid precursors***

The yield of CD34⁺, myeloid/lymphoid precursor is shown in Table 1.

5

TABLE 1

Sample	Volume	MNC	CD34⁺	Myeloid precursor	Lymphoid precursor
CB 20	50 ml	350 x 10 ⁶	5.8 x 10 ⁶	0.6 x 10 ⁶	0.12 x 10 ⁶
CB 53	50 ml	300 x 10 ⁶	4 x 10 ⁶	0.5 x 10 ⁶	0.02 x 10 ⁶
CB 56	55 ml	310 x 10 ⁶	3.5 x 10 ⁶	0.3 x 10 ⁶	0.04 x 10 ⁶
CB 30*	-	360 x 10 ⁶	1.8-2.5 x 10 ⁶	-	-

Purity CD34⁺ cells: >98%

10

* Pranke, *Acta Haematologica* 105: 71-76, 2001

15

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Dangl and Herzenberg, *J. Immunol. Methods* 52: 1-14, 1982

Darzynkiewica, Z. and Crissman, H.A., eds., Academic Press) "*Methods in Cell Biology*"
Vol. 33,

Grouard *et al.*, *J. Exp. Med.* 185: 1101-1111, 1997.

Hart, *Blood* 90: 3245-3287, 1997.

Mahvi *et al.*, *Immunology and Cell Biology* 75: 456-460, 1997.

Pranke, *Acta Haematologica* 105: 71-76, 2001

Roit, Brostoff, Male: 6th Edition, *Immunology*

CLAIMS

1. A method for generating a population of dendritic cells comprising culturing or expanding CD34⁺ precursor cells in the presence of one or more cytokines for a time and under conditions sufficient to allow said CD34⁺ precursor cells to differentiate into a population of dendritic cells.
2. A method for differentiating a population of CD34⁺ precursor cells into dendritic cells comprising exposing said CD34⁺ precursor cells to one or more cytokines for a time and under conditions sufficient to allow said CD34⁺ precursor cell to differentiate into dendritic cells.
3. A method of inducing a gradient of differentiated dendritic cells from a population of CD34⁺ precursor cells, comprising culturing or expanding CD34⁺ precursor cells in the presence of one or more cytokines for a time and under conditions sufficient to allow said isolated CD34⁺ precursor cells to differentiate into a population of dendritic cells.
4. A method for proliferating a population of CD34⁺ precursor cells and differentiating the expanded population into dendritic cells, comprising:
 - (a) isolating CD34⁺ precursor cells from a subject;
 - (b) expanding said population of CD34⁺ precursor cells; and
 - (c) culturing said expanded population of CD34⁺ precursor cells in the presence of one or more cytokines for a time and under conditions sufficient to allow said isolated CD34⁺ precursor cells to differentiate into a population of dendritic cells.
5. A method for differentiating a population of CD34⁺ precursor cells into a population of dendritic cells and proliferating said dendritic cells into an expanded population into dendritic cells, comprising:

- 25 -

- (a) isolating CD34⁺ precursor cells from a subject;
- (b) culturing said isolated CD34⁺ precursor cells in the presence of one or more cytokines for a time and under conditions sufficient to allow said isolated CD34⁺ precursor cells to differentiate into a population of dendritic cells;
and
- (c) expanded said population.

6. The method of any one of claims 1 to 6, wherein said CD34⁺ precursor cell is isolated from a biological sample selected from the group consisting of peripheral blood, PBCMs, stem cells, monocytes, amniotic fluid, chorionic villus, cord blood, and tissue.

7. The method according to any one of claims 1 to 5, wherein said population of CD34⁺ precursor cells is differentiated into a specific lineage of dendritic cells selected from the group consisting of myeloid dendritic cells, lymphoid dendritic cells, Langerhans cells, interstitial dendritic cells, Afferent lymph veiled cells, blood dendritic cells and interdigitating cells.

8. The method of claim 7, wherein said population of CD34⁺ precursor cell is differentiated into a heterogenous population of dendritic cells.

9. The method of claim 7, wherein said population of CD34⁺ precursor cells is differentiated into a substantially homogenous population of dendritic cells.

10. The method of any one of claims 1 to 5, wherein the cytokine is selected from the group consisting of flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF, TNF- α , IL-4, TNF- β , LT- β , IL-2, IL-7, IL-9, IL-15, IL-13, IL-5, IL-1 α , IL-1 β , IFN- γ , IL-10, IL-17, IL-16, IL-18, HGF, IL-11, MSP, FasL, TRAIL, TRANCE, LIGHT, TWEAK, CD27L, CD30L, CD40L, APRIL, TALL-1, 4-1BBL, OX40L, GITRL, IGF-I, IGF-II, HGF, MSP, FGF-a, FGF-b,

- 26 -

FGF-3-19, NGF, BDNF, NTs, Tpo, Epo, Ang1-4, PDGF-AA, PDGF-BB, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, EGF, TGF- α , AR, BTC, HRGs, HB-EGF, SMDF, OB, CT-1, CNTF, OSM, SCF, Flt-3L, M-CSF, MK and PTN or their functional, recombinant or chemical equivalents or homologues thereof.

11. The method of claim 10, wherein the cytokine is selected from the group consisting flt3, SCF, IL-3, IL-6, GM-CSF, G-CSF, TNF- α or their functional, recombinant or chemical equivalents or homologues thereof.

12. The method of any one of claims 1 to 5, further comprising presenting a peptide on the surface of the dendritic cells, thereby providing a population of antigen presenting dendritic cells.

13. The method of claim 12, wherein said antigen presenting cell is capable of activating a population of T cells.

14. The method of claim 13, wherein said population of T cells occurs *in vitro*.

15. The method of claim 13, wherein said population of T cells occurs *in vivo*.

16. The method of any one of claims 13 to 15, wherein the T cell is selected from a population of CD4⁺ T cells and/or CD8⁺ T cells.

17. The method of claim 13, wherein said peptide is derived from a polypeptide isolated from a human protein, a pathogen protein or a protein derived from a cancer cell.

18. The method of claim 17, wherein said pathogen is selected from the group consisting of viruses, bacteria, fungi, ectoparasites, mycoplasmas, *Archea*, algae, oomycetes, slime molds, nematodes and amoebae.

- 27 -

19. The method of claim 18, wherein said virus is selected from the group consisting of Human Immunodeficiency Virus (HIV), the human papilloma virus, Epstein-Barr virus, the polio virus, the rabies virus, the Ebola virus, the influenza virus, the encephalitis virus, smallpox virus, the rabies virus, the herpes viruses, the sendai virus, the respiratory syncytial virus, the orthomyxoviruses, the measles viruses, the vesicular stomatitis virus, visna virus and cytomegalovirus.

20. The method of claim 18, wherein said fungi is selected from the group consisting of *Acremonium* spp., *Aspergillus* spp., *Basidiobolus* spp., *Bipolaris* spp., *Blastomyces dermatidis*, *Candida* spp., *Cladophialophora carrionii*, *Coccidioides immitis*, *Conidiobolus* spp., *Cryptococcus* spp., *Curvularia* spp., *Epidermophyton* spp., *Exophiala jeanselmei*, *Exserohilum* spp., *Fonsecaea compacta*, *Fonsecaea pedrosoi*, *Fusarium oxysporum*, *Fusarium solani*, *Geotrichum candidum*, *Histoplasma capsulatum* var. *capsulatum*, *Histoplasma capsulatum* var. *duboisii*, *Hortaea werneckii*, *Lacazia loboi*, *Lasiodiplodia theobromae*, *Leptosphaeria senegalensis*, *Madurella grisea*, *Madurella mycetomatis*, *Malassezia furfur*, *Microsporum* spp., *Neotestudina rosatii*, *Onychocola canadensis*, *Paracoccidioides brasiliensis*, *Phialophora verrucosa*, *Piedraia hortae*, *Piedra ia hortae*, *Pityriasis versicolor*, *Pseudallesheria boydii*, *Pyrenochaeta romeroi*, *Rhizopus arrhizus*, *Scopulariopsis brevicaulis*, *Scytalidium dimidiatum*, *Sporothrix schenckii*, *Trichophyton* spp., *Trichosporon* spp., Zygomycete fungi, *Absidia corymbifera*, *Rhizomucor pusillus* and *Rhizopus arrhizus*.

21. The method of claim 18, wherein said bacteria are selected from the group consisting of *Bacillus anthracis*, *Bordetella pertussis*, *Vibrio cholerae*, *Escherichia coli*, *Shigella dysenteriae*, *Clostridium perfringens*, *Clostridium botulinum*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Pseudomonas aeruginosa*, *Bacillus anthracis*, *Bordetella pertussis*, *Staphylococcus aureus* and *Streptococcus pyogenes*.

22. The method of claim 17, wherein said cancer cell is isolated from a cancer cell associated with a cancer selected from the group consisting of ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid

- 28 -

Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumours, Breast Cancer, CNS tumours, Carcinoid Tumours, Cervical Cancer, Childhood Brain Tumours, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma-protuberans, Desmoplastic-Small-Round-Cell-Tumour, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumour, Genitourinary Cancers, Germ Cell Tumours, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer, Hereditary Breast Cancer, Histiocytosis, Hodgkin's Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's-Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumour-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage Syndrome, Non-Melanoma Skin Cancer, Non-Small-Cell-Lung-Cancer-(NSCLC), Ocular Cancers, Oesophageal Cancer, Oral cavity Cancer, Oropharynx Cancer, Osteosarcoma, Ostomy Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral-Neuroectodermal-Tumours, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare-cancers-and-associated-disorders, Renal Cell Carcinoma, Retinoblastoma,

- 29 -

Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumours, Squamous-Cell-Carcinoma- (skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-Cancer-(renal-pelvis/-ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's-Macroglobulinemia, Wilms' Tumour.

23. The method of claim 17, wherein the human protein is associated with an autoimmune disease.

24. The method of claim 23, wherein the autoimmune disease is selected from the group consisting of Addisons Disease, Allergies, Anemia, Ankylosing Spondylitis, Arthritis, Celiac Disease, Crohns Disease, Diabetes, Endometriosis, Fibromyalgia, Graves Disease, Hashimotos Disease, Hypothyroidism, Immune Diseases, Lupus, Lymphoma, Meniere's Disease, Multiple Sclerosis, Oral Diseases, Osteoporosis, Pleurisy, Psoriasis, Reiters Syndrome, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogrens Syndrome, Thrush, Vitiligo, Alopecia Areata, Antiphospholipid-Syndrome (APS), Behcet's Disease, Ulcerative Colitis, Goodpasture Syndrome, Graft Versus Host Disease, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myositis, Pemphigus Vulgaris, Primary Biliary Cirrhosis, Rheumatic Fever, Vasculitis and Wegener's Granulomatosis.

25. A method for inducing a protective immune response against an autoimmune disease in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting dendritic cell generated according to claim 23.


26. The method of claim 23, wherein the autoimmune disease is selected from the group consisting of Addisons Disease, Allergies, Anemia, Ankylosing Spondylitis, Arthritis, Celiac Disease, Crohns Disease, Diabetes, Endometriosis, Fibromyalgia, Graves

- 30 -

Disease, Hashimoto's Disease, Hypothyroidism, Immune Diseases, Lupus, Lymphoma, Meniere's Disease, Multiple Sclerosis, Oral Diseases, Osteoporosis, Pleurisy, Psoriasis, Reiter's Syndrome, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Thrush, Vitiligo, Alopecia Areata, Antiphospholipid Syndrome (APS), Behcet's Disease, Ulcerative Colitis, Goodpasture Syndrome, Graft Versus Host Disease, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myositis, Pemphigus Vulgaris, Primary Biliary Cirrhosis, Rheumatic Fever, Vasculitis and Wegener's Granulomatosis.

27. A method for inducing a protective immune response against cancer in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting dendritic cell generated according to claim 22.

27. A method for inducing a protective immune response against a pathogen in a subject comprising administering to said subject in need of treatment a therapeutically effective amount of a composition comprising an antigen-presenting dendritic cell generated according to any one of claims 17 to 21.



All Data derived from myeloid precursor

Similar results from 4 exp.

Figure 1

2/8





Figure 2

3/8





Figure 3

4/8



R1*R2 → CD14⁺CD15⁺Progeny




Figure 4

5/8




Figure 5

6/8




Figure 5(i)

7/8






Figure 5ii





Figure 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/01113

A. CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. ⁷ : C12N 5/02					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) IPC (WPIDS) AND CHEMICAL ABSTRACTS					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE BELOW					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, MEDLINE, CA					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	Journal of Leukocyte Biology, 1 August 2002, vol. 72, Bontkes et al., "Expansion of dendritic cell precursors from human CD34+ progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome", pages 321-9	1-27			
X Y	The Journal of Immunology, 2001, vol. 166, Curti et al., "Stem Cell Factor and FLT3-Ligand Are Strictly Required to Sustain the Long-Term Expansion of Primitive CD34+DR- Dendritic Cell Precursors", pages 848-54	1-27			
X Y	British Journal of Haematology, 1997, vol. 99, Herbst et al., "CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis", pages 490-9	1-27			
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 33%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> <td style="width: 33%;"></td> </tr> </table>			<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>	
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>				
Date of the actual completion of the international search 3 October 2003		Date of mailing of the international search report 14 OCT 2003			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer CHRISTOPHER LUTON Telephone No : (02) 6283 2256			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/01113

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos : **1-27 (partially)**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
SEE SUPPLEMENTAL BOX

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

SEE SUPPLEMENTAL BOX

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01113

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: I & II

The nature of the invention is not clear.

The specification states that the inventive concept relates to the use of cytokines to induce CD34+ cells to differentiate into dendritic cells. However, the use of cytokines to induce CD34+ cells to differentiate into dendritic cells would appear to be common general knowledge in the art:

- Blood. 2002 Jul;100(2):701-703, Materson et al.
- J Immunother. 2000 Jan;23(1):48-58
- J Hematother Stem Cell Res. 2001 Aug;10(4):569-78, Loudovaris et al.
- Cytotherapy. 2000;2(2):95-104, Enomoto et al.
- Immunol Cell Biol. 2002 Jun;80(3):216-25, Monji et al.

Therefore, there can only be an invention in the use of a specific cytokine or combination of cytokines. Different cytokines or combinations of cytokines would represent separate inventions. The limited examples provided in the specification only demonstrate the use of one particular combination of cytokines, viz; flt3-ligand, SCF, IL-3 and IL-6.

The specification appears to indicate that one aspect of the invention may relate to the pre-sorting of CD34+ cells into myeloid and lymphoid precursors prior to differentiation into dendritic cells (page 6, lines 26-29 and page 8, lines 15-25). The specification describes only one method by which this sorting may be achieved, viz; the use of FACS to isolate CD33(+)CD7(-)CD10(-) and CD33(+/-)CD7(+)CD10(+) populations.

The technical features of the invention are therefore considered to be either:

- the use of flt3-ligand, SCF, IL-3 and IL-6 in the differentiation of CD34+ cells into dendritic cells, or
- the pre-sorting of CD34+ cells into CD33(+)CD7(-)CD10(-) and CD33(+/-)CD7(+)CD10(+) populations prior to induction of differentiation into dendritic cells.

The wording of the claims does not limit them to the technical features of the invention as described by the specification (Rule 6.3(a)). Consequently, the claims do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out on the full scope of the claims.

Therefore, the scope of the claims has only been partially searched to the extent that they are limited to the technical features stated in the preceding paragraph.

The two sets of technical features identified above are considered to represent separate inventions. However, as all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.